{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-000369","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2022-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.994172+00:00","generated_at":"2026-06-27T16:52:04.882546+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FDA clears IND for Compass Therapeutics' CTX-009 Phase 2 study in biliary tract cancers","bullets":["FDA cleared IND for CTX-009 bispecific antibody targeting DLL4 and VEGF-A.","Enables global Phase 2 trial in advanced biliary tract cancers including cholangiocarcinoma.","Will expand ongoing South Korean Phase 2; US clinical sites expected to open in Q2 2022.","CEO Thomas Schuetz noted CTX-009 has potential as important new therapy for BTC patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-000369","json":"https://secwatch.observer/filing/0001171843-22-000369.json","markdown":"https://secwatch.observer/filing/0001171843-22-000369.md","text":"https://secwatch.observer/filing/0001171843-22-000369.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322000369/0001171843-22-000369-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322000369/f8k_012022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T16:52:04.882546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}